Deciphering the Role of Claudins in Lung Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 4

PMID 39364319

Authors

Tarek Ziad Arabi

Wael Alkattan

Nadine Ashraf Osman

Belal Nedal Sabbah

Nader Ashraf

Abderrahman Ouban

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains a major global health challenge, characterized by aggressive malignancy and poor prognostic outcomes. This review article focuses on the pivotal role of claudins, a family of tight junction proteins, in the pathophysiology of lung cancer. Claudins are integral to maintaining epithelial barrier function and cellular polarity, yet they are intricately involved in the progression and metastasis of lung cancer. The aberrant expression of claudins has been observed across various histological subtypes of lung cancer, indicating their potential as diagnostic and prognostic biomarkers. Specifically, claudins such as claudin-1, -2, -3, -4, and -7 exhibit diverse expression patterns that correlate with tumor aggressiveness, patient survival rates, and response to therapies. Inflammation and cytokine modulation significantly influence claudin expression, affecting tumor microenvironment dynamics and cancer progression. This review also highlights the therapeutic implications of targeting claudins, particularly in cases resistant to conventional treatments. Recent advances in this area suggest that claudin-modulating agents may enhance the efficacy of existing therapies and offer new avenues for targeted interventions. By integrating the latest research, this article aims to provide a comprehensive understanding of claudin's roles in lung cancer and encourages further clinical trials to explore claudin-targeting therapies. This could pave the way for more effective management strategies, improving outcomes for lung cancer patients.

References

Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P . CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023; 29(11):2844-2853. PMC: 10667102. DOI: 10.1038/s41591-023-02612-0. View

Arai W, Konno T, Kohno T, Kodera Y, Tsujiwaki M, Shindo Y . Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells. Oncotarget. 2023; 14:261-275. PMC: 10038356. DOI: 10.18632/oncotarget.27728. View

Wu J, Wu Y, Tung C, Tsai Y, Chen H, Chen Y . DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. Theranostics. 2020; 10(19):8903-8923. PMC: 7392003. DOI: 10.7150/thno.45785. View

Ordonez N . Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am J Clin Pathol. 2013; 139(5):611-9. DOI: 10.1309/AJCP0B3YJBXWXJII. View

Piontek A, Eichner M, Zwanziger D, Beier L, Protze J, Walther W . Targeting claudin-overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin. Mol Oncol. 2019; 14(2):261-276. PMC: 6998413. DOI: 10.1002/1878-0261.12615. View

Wang D, Zhang W, Danil G, Yang K, Hu J . The role and mechanism of claudins in cancer. Front Oncol. 2023; 12:1051497. PMC: 9818346. DOI: 10.3389/fonc.2022.1051497. View

Soini Y . Claudins in lung diseases. Respir Res. 2011; 12:70. PMC: 3128860. DOI: 10.1186/1465-9921-12-70. View

Peto J, Decarli A, La Vecchia C, Levi F, Negri E . The European mesothelioma epidemic. Br J Cancer. 1999; 79(3-4):666-72. PMC: 2362439. DOI: 10.1038/sj.bjc.6690105. View

Liu Y, Sun W, Zhang K, Zheng H, Ma Y, Lin D . Identification of genes differentially expressed in human primary lung squamous cell carcinoma. Lung Cancer. 2007; 56(3):307-17. DOI: 10.1016/j.lungcan.2007.01.016. View

10.

Mao S, Zheng S, Lu Z, Wang X, Wang Y, Zhang G . Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1. Transl Lung Cancer Res. 2021; 10(7):3155-3172. PMC: 8350081. DOI: 10.21037/tlcr-21-356. View

11.

Ma S, Li Q, Peng J, Zhouwen J, Diao J, Niu J . Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis. CNS Neurosci Ther. 2017; 23(12):947-960. PMC: 6492739. DOI: 10.1111/cns.12764. View

12.

Tsao A, Wistuba I, Roth J, Kindler H . Malignant pleural mesothelioma. J Clin Oncol. 2009; 27(12):2081-90. PMC: 4881753. DOI: 10.1200/JCO.2008.19.8523. View

13.

Koval M . Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol. 2012; 75:551-67. DOI: 10.1146/annurev-physiol-030212-183809. View

14.

Che J, Yang Y, Xiao J, Zhao P, Yan B, Dong S . Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma. Tumour Biol. 2015; 36(8):6559-68. DOI: 10.1007/s13277-015-3350-1. View

15.

Ikari A, Sato T, Watanabe R, Yamazaki Y, Sugatani J . Increase in claudin-2 expression by an EGFR/MEK/ERK/c-Fos pathway in lung adenocarcinoma A549 cells. Biochim Biophys Acta. 2012; 1823(6):1110-8. DOI: 10.1016/j.bbamcr.2012.04.005. View

16.

Zhao Z, Li J, Jiang Y, Xu W, Li X, Jing W . CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation. Med Sci Monit. 2017; 23:2906-2916. PMC: 5479443. DOI: 10.12659/msm.904177. View

17.

Arafah M, Raddaoui E, Kassimi F, Alhamad E, Alboukai A, Alshedoukhy A . Endobronchial biopsy in the final diagnosis of chronic obstructive pulmonary disease and asthma: a clinicopathological study. Ann Saudi Med. 2018; 38(2):118-124. PMC: 6074367. DOI: 10.5144/0256-4947.2018.118. View

18.

Che J, Yue D, Zhang B, Zhang H, Huo Y, Gao L . Claudin-3 Inhibits Lung Squamous Cell Carcinoma Cell Epithelial-mesenchymal Transition and Invasion via Suppression of the Wnt/β-catenin Signaling Pathway. Int J Med Sci. 2018; 15(4):339-351. PMC: 5835704. DOI: 10.7150/ijms.22927. View

19.

McDonagh D, Vollmer R, Shelburne J . Intercellular junctions and tumor behavior in lung cancer. Mod Pathol. 1991; 4(4):436-40. View

20.

Alnajjar S, Nolte I, Becker A, Schille J, Trakooljul N, Frank M . Ablation of Red Stable Transfected Claudin Expressing Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cell Lines by C-CPE Gold-Nanoparticle-Mediated Laser Intervention. Int J Mol Sci. 2021; 22(22). PMC: 8618062. DOI: 10.3390/ijms222212289. View